Summary: Researchers tested a multi-step immunotherapy designed to retrain the immune system to control HIV without continuous antiretroviral drugs. After stopping standard HIV medication, seven of ten trial participants sustained low viral levels for months, and one showed no measurable viral rebound.
The regimen combined a therapeutic vaccine that boosts virus-targeting T cells with broadly neutralizing antibodies aimed at reducing viral reservoirs. These findings offer rare evidence that durable, drug-free control of HIV may be achievable and point to a new direction for cure-focused research.
Key facts
- Sustained control: 70% of participants maintained low HIV levels after interrupting daily antiretroviral therapy (ART).
- Immune reprogramming: A therapeutic vaccine plus targeted antibody therapy enhanced T-cell responses capable of suppressing the virus.
- Delayed rebound: Only three participants experienced the rapid viral rebound typically seen within weeks of stopping ART.
Source: UCSF
Overview
A team at the University of California, San Francisco (UCSF) reports that a combination immunotherapy can induce sustained control of HIV in people who stopped their antiretroviral drugs. The small, single-arm proof-of-concept trial enrolled ten people living with HIV who had been taking ART; most had started ART soon after infection, which preserved stronger immune responses.
Published Dec. 1 (World AIDS Day) in Nature, the study tested a three-part strategy: a therapeutic vaccine to stimulate HIV-specific T cells, a duo of broadly neutralizing antibodies (bNAbs) given while ART was suppressing virus levels to reduce reservoirs, and a repeat antibody dose at the time of ART interruption. A toll-like receptor 9 agonist was also administered to enhance immune activation during the antibody phase.
When people living with HIV stop ART, the virus typically rebounds within about two weeks and rises rapidly. In this trial, only three participants experienced that classic rapid rebound. Six maintained low-level viremia for months after stopping ART, and one participant showed no viral rebound during the follow-up period reported.
How the immune response changed
Investigators analyzed immune responses in participants who controlled the virus. Those people displayed rapid and robust expansion of activated CD8+ T cells when exposed to rebounding virus. Researchers described these T cells as poised and ready—like a cat preparing to pounce—and able to proliferate quickly, limiting viral replication after ART was stopped.
The observed association between brisk CD8+ T-cell expansion and lower median viral loads following peak viremia suggests that improving T-cell quality and responsiveness is a critical mechanism for sustained ART-free control.
Implications and next steps
Although the results are encouraging, the trial was small and lacked a randomized control arm. The treatment protocol is complex and would need simplification, optimization, and testing in larger, controlled studies before being considered as an alternative to standard lifelong ART.
UCSF investigators emphasize that this is not a cure yet, but the data provide strong proof of concept that combination immunotherapy can slow viral rebound and improve immune control. The approach merits further development as part of a broader effort to achieve long-term, drug-free remission for people living with HIV.
Study authors and support
Co-senior authors include Steven Deeks, MD, and Rachel Rutishauser, MD, PhD. The first author was Michael Peluso, MD. Additional UCSF contributors named in the report include Demi Sandel, PhD; Amelia Deitchman, PharmD, PhD; Steven Yukl, MD; Timothy Henrich, MD; Matthew Spitzer, PhD; David Glidden, PhD; and many others across clinical and laboratory teams.
The trial was made possible by a multi-year partnership between amfAR (the Foundation for AIDS Research) and UCSF and received support from the National Institutes of Health and several foundation and institutional awards. Funding details and grant numbers are reported in the original paper.
Key questions answered
Q: Can HIV be controlled without lifelong antiviral drugs?
A: In this small clinical trial, most participants maintained low virus levels for months after stopping standard HIV medication, indicating that long-term ART-free control may be achievable.
Q: How did researchers achieve this control?
A: A combination of therapeutic vaccination, immune stimulation, and administration of broadly neutralizing antibodies appeared to retrain and empower CD8+ T cells to suppress viral rebound.
Q: Is a cure for HIV/AIDS now within reach?
A: These results are not a cure, but they provide compelling proof of concept that combination immunotherapy can slow rebound and enable immune-mediated control, justifying larger, controlled trials.
Editorial notes
- This article was edited by a Neuroscience News editor.
- The full journal paper was reviewed for accuracy.
- Additional context was added by staff to clarify implications and next steps.
About this research
Author: Laura Kurtzman, UCSF
Source: UCSF
Contact: Laura Kurtzman – UCSF
Image credit: Neuroscience News
Original research: Correlates of HIV-1 control after combination immunotherapy, Steven Deeks et al., published in Nature. The published study presents a single-arm, proof-of-concept trial (NCT04357821) combining therapeutic vaccination, administration of two bNAbs (10-1074 and VRC07-523LS), and a TLR9 agonist with repeat bNAb dosing at ART interruption.
Abstract (summary)
Inducing sustained ART-free control of HIV is a high priority. Preclinical studies combining vaccination, latency reversal, and passive antibody transfer have shown promise. In this study of ten people on suppressive ART, seven participants exhibited control of viremia after intervention and ART interruption. Control correlated with rapid expansion of activated CD8+ T cells in response to rebounding virus. These results support continued optimization of combination immunotherapy approaches to slow viral rebound and enhance T-cell responses to achieve durable remission.